CryOSA, Inc.

Based in Arden Hills, US, CryOSA, Inc. is a medical device company dedicated to developing a novel treatment for obstructive sleep apnea, focusing on non-invasive solutions to improve patient comfort. CryOSA, Inc. is primarily engaged in creating innovative therapies for moderate to severe obstructive sleep apnea (OSA).

Founded in 2018, the company has raised a total of USD 21. 5 mn, comprising a USD 21. 5 mn Series B funding round led by Solas BioVentures in September 2021, and prior financing rounds including an USD 8. 25 mn Series A-2 round in June 2020.

The company is headquartered in Arden Hills, US, and was founded by Donald Gonzales, with Laura Stoltenberg and Mark Christopherson serving as key executives. CryOSA has completed four deals since inception, with its latest funding round being instrumental for its continued development efforts. CryOSA primarily focuses on developing an innovative treatment for moderate to severe obstructive sleep apnea (OSA). Their core value proposition lies in creating a mask-free, hose-free, and implant-free solution that addresses the limitations of existing therapies, which often involve cumbersome positive airway pressure devices or invasive surgical procedures.

The company targets a significant unmet need, as millions of individuals globally, approximately 1 billion, suffer from OSA and many find current treatment options intolerable. Cryosa's breakthrough technology is currently in the clinical stage, with a notable milestone of treating the first patient in the U. S. as of January 2024.

With a focus on North American and European markets, Cryosa is poised to reach both healthcare providers and patients seeking effective alternatives to conventional OSA therapies. Cryosa's revenue model is structured around advancing its minimally invasive OSA treatment through partnerships and clinical studies, rather than traditional retail sales. The company has successfully completed multiple funding rounds, including a USD 21. 5 mn Series B round in September 2021 and an USD 8.

25 mn Series A-2 funding in June 2020, which are critical to its development efforts. While specific pricing plans are not disclosed, the revenue-generating strategy likely involves collaborations with healthcare institutions and potential future licensing agreements with medical device distributors. The company's ongoing research and development efforts aim to enhance market entry strategies and patient access to its innovative solutions, targeting both healthcare providers and patients directly as the treatments progress through clinical validation and regulatory approvals. CryOSA plans to utilize the USD 21.

5 mn raised in its Series B funding round to continue its human clinical trials and further develop its sleep apnea treatment. The company is set to launch its innovative sleep apnea treatment in the U. S. following the successful completion of its clinical trials, marking a significant advancement in non-invasive therapy options.

Additionally, CryOSA aims to expand its presence in the North American and European markets over the coming years, leveraging recent funding to enhance its marketing strategies and partnerships with healthcare providers.